- Home
- LUCD vs ACIU Comparison
LUCD vs ACIU Comparison
Compare LUCD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | ACIU |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.8M | 221.9M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LUCD | ACIU |
|---|---|---|
| Price | $0.97 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.13 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.7M | 256.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | $706.75 |
| Revenue Next Year | $130.54 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.90 | $2.03 |
| 52 Week High | $1.63 | $4.00 |
Technical Indicators
Market Signals| Indicator | LUCD | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 42.42 |
| Support Level | N/A | $2.15 |
| Resistance Level | $1.11 | $2.66 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 21.63 | 30.39 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.